Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Core Viewpoint - Kuehn Law is investigating potential breaches of fiduciary duties by officers and directors of Amylyx Pharmaceuticals, Inc. related to misrepresentation of the company's drug RELYVRIO's commercial prospects [1] Group 1: Allegations Against Amylyx Pharmaceuticals - Insiders allegedly overstated the commercial prospects of RELYVRIO [1] - Patients reportedly discontinued treatment with RELYVRIO after six months [1] - The rate of new patients starting treatment with RELYVRIO was decreasing [1] - Consequently, the prescription rate for RELYVRIO was also overstated [1] - Insiders are accused of attempting to conceal these negative trends from investors by blocking analysts from accessing prescription data [1] - As a result, the company's public statements were materially false and misleading [1]